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 Abstract
The aim of this article is to present the safety and efficacy of intradetrusor botulinum toxin injections in the treatment 
of non-neurogenic overactive bladder in pediatric patients. 
The electronic database MEDLINE (1966-2009) was searched including the following entries: non-neurogenic 
overactive bladder and botulinum overactive bladder. Data on the investigation topic are scarce. 
Most of the papers concern neurogenic overactive bladder in adults, with only a few dealing with children with 
neurological disturbances. Therefore, the following paper presents a case of botulin toxin treatment in girl with 
overactive bladder. The patient did not tolerate the standard  anticholinergic therapy and did not present neurollogical 
disturbances. Successful outcome allows us to state that intradetrusor botulinum toxin type A injection is a promising 
new treatment method in the refractory cases of non-neurogenic pediatric overactive bladder. 
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Introduction
Overactive	 bladder	 (OAB)	 is	 characterized	 by	 involuntary	
and	unpredictable	 detrusor	muscle	 contractions,	 causing	 an	 in-
creased	micturition	frequency	accompanied	by	a	strong	desire	to	
void,	 leading	 to	 incontinence	episodes	 in	30%	of	patients.	The	
exact	 percentage	of	 children	 suffering	 from	 these	 symptoms	 is	
currently	not	known	but	epidemiological	studies	in	Europe	and	
the	United	States	show	that	this	condition	affects	around	16.5%	
of	 adult	 population	 [1,	 2].	 Currently	 anticholinergics	 are	 the	
mainstay	of	OAB	therapy	but	the	tolerability	of	these	agents	is	















A	 and	B	 have	 been	 used	 in	medicine.	The	 product	 containing	
serotype	A	of	botulinum	toxin	(BTX-A)	is	used	in	children	and	
currently	 is	 becoming	 a	 standard	 in	 the	 treatment	 of	 spasticity	
secondary	to	cerebral	palsy	[5].
The	 activity	 of	 botulinum	 toxin	within	 the	 neuromuscular	
junction	has	been	described	and	consists	of	inhibition	of	acetyl-
choline	release	at	the	presynaptic	level,	resulting	in	striated	mus-








Botulinum	toxin	has	been	found	 to	 inhibit	 the	 release	of	a	








trusor	overactivity	 in	adults	 there	 is	growing	evidence	 that	 this	
regimen	could	be	also	efficacious	in	children.	Further	support	for	
this	 strategy	 came	 from	 the	 case	of	14-year	old	neurologically	
intact	girl,	noncompliant	to	the	standard	anticholinergic	therapy.
Case report 












after	 2	months	 the	 girl	 became	 noncompliant,	 she	 stopped	 the	
therapy	and	all	 symptoms	relapsed.	Since	 the	patient	withdrew	
consent	 to	 oxybutynin	 chloride/desmopressin	 regimen,	 botuli-
num	 toxin	 was	 proposed	 instead.	After	 obtaining	 an	 informed	
consent	from	the	patient	and	her	parents,	100	U	of	BTX-A	(Bo-
tox)	was	given	in	20	intradetrusor	injections	sparing	trigone.	The	
rigid	 cystoscope	was	used	 (diameter	 9mm)	 and	procedure	was	
performed	 under	 short-time	 general	 anesthesia	 which,	 in	 our	
opinion,	 is	obligatory	 in	pediatric	patients	due	 to	high	 level	of	





Celem pracy była analiza bezpieczeństwa i skuteczności podawanej dopęcherzowo toksyny botulinowej u dzieci 
z zespołem pęcherza nadreaktywnego o podłożu nieneurogennym. 
Korzystając z bazy danych MEDLINE dokonano analizy piśmiennictwa opublikowanego w latach 1966-2009. 
Wyszukiwanie artykułów przeprowadzono w oparciu o następujące terminy: non-neurogenic overactive bladder, 
botulinum overactive bladder. 
Ogromna większość publikacji dotyczy zastosowania toksyny botulinowej u dorosłych lub dzieci z neurogenną 
postacią zespołu pęcherza nadreaktywnego. Zaskakująca jest niewielka liczba artykułów dotyczących zastosowania 
toksyny botulinowej u dzieci z nieneurogenną postacią zespołu pęcherza nadreaktywnego. Z tego względu praca 
została uzupełniona prezentacją przypadku skutecznej terapii toksyną botulinową u dziewczynki bez zaburzeń 
neurologicznych, zgłaszającej objawy pęcherza nadreaktywnego, jednak nie tolerującej terapii lekami o działaniu 
antycholinergicznym.
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issue.	 In	animal	studies	 the	 lethal	dose	of	botulinum	toxin	was	
39-40U/kg	 [16].	By	extrapolation	one	can	calculate	 that	 for	an	
adult	person	weighing	70	kg	 the	 lethal	dose	will	be	as	high	as	
2800U.	 In	urogynecology	usually	a	single	dose	doesn’t	exceed	















contraindications	 to	 injection	 of	 botulinum	 toxin	 are:	 motoric	







(range:	 10-50),	BTX-A	was	 given	 in	 the	 bladder	wall,	 sparing	
the	 trigone,	 under	 rigid	 cystoscopic	 guidance	 and	 under	 gen-
eral	anesthesia.	Efficacy	of	treatment	was	measured	in	terms	of	 
continence	 restoration	 and	 urodynamic	 findings.	The	mean	 re-






















8-14	 years)	who	were	 given	 100IU	 of	Botox,	with	 12	months	
follow-up	in	15	patients.	After	first	injection,	9	patients	showed	
a	full	 response	as	defined	by	the	authors	as	no	urgency	and	no	















of	 botulinum	 toxin	 is	 limited	 by	 the	 lack	 of	 controlled	 studies	
and	the	fact	that	most	of	the	studies	involved	small	numbers	of	
individuals.
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